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For many years, the understanding of gastrointestinal stromal tumors (GISTs), which are the most common
mesenchymal tumors of the gastrointestinal tract, has been very limited. However, it is now possible to provide a
more precise definition through the use of pathology classification and molecular techniques. Coupled with the
advancement of clinical practice, especially the development of targeted therapy, there is now a much better
insight into its treatment. At present, organizations such as the National Comprehensive Cancer Network in the USA
and the European Society for Medical Oncology in Europe have established a consensus and drawn up guidelines
for the diagnosis, treatment, and follow-up of GISTs.
With experts coming from various districts in Taiwan and combining the most recent clinical data and experiences,
the Taiwan Surgical Society of Gastroenterology drafted the first national GIST treatment guidelines after a
consensus meeting in 2007. Following subsequent advances in GIST diagnosis and treatment, further revisions and
modifications have been made to the original guidelines. We present here the updated consensus and
recommendations of the Taiwan Surgical Society of Gastroenterology for the diagnosis and treatment of GIST. We
hope these guidelines can help enhance the quality of diagnosis, treatment, and care of patients with GIST in
Taiwan.
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Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumor of the gastrointestinal tract,
and account for 5% of all sarcomas [1]. Although GISTs
are relatively rare tumors, the reported incidence has
increased since the early 1990s, owing to increased
awareness and appropriate diagnosis of this tumor type.
In Taiwan, the annual incidence of GIST is 13.74 per
million populaton [2], consistent with studies from other
countries ,which show annual incidences of 11 to 19.6
per million population [3-7]. In general, only complete
resection can lead to cure, although recurrence is com-
mon after surgery. Before the advent of targeted therap-
ies, the prognosis for advanced GISTs was poor, owing to
their inherent resistance to conventional chemotherapy
and radiotherapy [8]. The identification of thje signal-* Correspondence: chenmf#adm.cgmh.org.tw
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reproduction in any medium, provided the ortransduction pathway associated with the development
of GISTs and the use of molecular targeted therapies,
such as imatinib mesylate (Gleevec/Glivec; Novartis
Pharmaceuticals, Basel, Switzerland), have dramatically
improved the survival and quality of life of patients with
GISTs over recent years.
In western countries, several organizations including
the National Comprehensive Cancer Network (NCCN)
and the European Society of Medical Oncology (ESMO)
have published updated guidelines for the diagnosis and
management of GIST [9-11]. In Taiwan, the Taiwan
Surgical Society of Gastroenterology (TSSG) drafted the
first national GIST treatment guidelines after a consen-
sus meeting involving experts from across the country in
2007 (unpublished data). Following subsequent advances
and developments, the group of experts conducted a series
of meetings to review more recent evidence and made
modifications to the original guidelines. This review pre-
sents the updated consensus and recommendations of
the TSSG as a basis for guidelines for the diagnosis and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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shows the levels of evidence [I to V] and grades of
recommendation [A to D], as used by the American Soci-
ety of Clinical Oncology [12].
Disease background
As first reported in 1998, 95% of GISTs are immunohis-
tochemically positive for the receptor tyrosine kinase
KIT (also known as CD117) [13]. In addition, Hirota and
colleagues found that in most GISTs, the KIT protein
has been mutated, leading to constitutive activation of
the kinase [13,14]. It is now known that 70 to 80% of
GISTs harbor a KIT mutation. Most KIT mutations
occur in the juxtamembrane domain encoded by KIT
exon 11, and some have been detected in the extracellu-
lar domain encoded by exon 9. KIT mutations have also
been identified in the tyrosine kinase domain (exons 13
and 17), although these are rare [15,16]. A subset of
GISTs that lack KIT gene mutations harbor an activating
mutation in the gene encoding platelet-derived growth
factor receptor alpha (PDGFRA) [3]. KIT and PDGFRA
mutations are mutually exclusive, and are associated
with distinct clinicopathologic features. For example,
GISTs with KIT exon 9 mutations are often located in
the small bowels, whereas PDGFRA-mutated GISTs are
commonly found in the stomach [17,18]. The PDGFRA
mutation is present in about 5% of GISTs in western
patients, but the mutation rate is much lower in Taiwan-
ese patients (about 1%) [3,19]. About 10 to 15% of GISTs
do not have a detectable mutation in either KIT or
PDGFRA, and are often referred to as ‘wild-type’ GISTs.
KIT remains a key diagnostic marker for this tumor
type, and mutant KIT and PDGFRA proteins have be-
come crucial therapeutic targets in GISTs.
GISTs are predominantly found in middle-aged to
older adults, and are extremely rare in patients younger
than 30 years [20]. The median age at diagnosis has been
reported to be in the range of 63 to 69 years [6,7,21].
The most common primary sites for GISTs are the
stomach (60%) and small intestine (30%), with theTable 1 Levels of evidence and grades of recommendation
Level Source of evidence
I Meta-analysis of multiple well-designed, controlled studies;
randomized trials with low rates of false-positive and low false-
negative errors (high power)
II At least one well-designed experimental study; randomized tria
high rates of false-positive and high false-negative errors (low p
III Well-designed, quasi-experimental studies such as non-random
controlled, single-group, preoperative and correlation descriptiv
studies, and case studies
IV Well-designed, non-experimental studies such as comparative a
correlation descriptive studies, and case studies
V Case reports and clinical examplesduodenum (5%), colorectum (< 5%), and esophagus and
appendix (<1%) being less common sites [22,23]. Recur-
rence after resection is predominantly intra-abdominal,
and the liver is the most common site of recurrence in
both patients with a primary tumor and those with
metastatic disease at presentation [1].
In general, patients with suspected GIST may present
with various symptoms, including, but not limited to,
early satiety, fatigue secondary to anemia, intraperito-
neal hemorrhage, intra-luminal gastrointestinal bleed-
ing, or abdominal discomfort from pain or swelling.
Some patients may present with an acute abdomen as
result of tumor rupture, gastrointestinal obstruction, or
appendicitis-like pain, which requires immediate medical
attention.Diagnosis
Clinical diagnosis
We recommend that potentially resectable GISTs of any
size, other than tumors found in the stomach, should be
referred to a general surgeon for resection. Suspected
gastric nodules 20 mm or larger in size should be surgi-
cally resected, because, if diagnosed as GIST, will imply
a higher risk [9-11]. Nodules smaller than 20 mm, if
diagnosed as GIST, may be low-risk, and their clinical
significance remains questionable. However, we recom-
mend that patients with suspected gastric GIST smaller
than 20 mm should be referred for resection if any of
the following is present: 1) nodule with irregular margin,
signs of ulceration or bleeding, or an increase in size
during follow-up; 2) presence of cystic change, necrosis,
heterogeneous echogenecity, or lobulation, or if there is
poor patient compliance with follow-up; or 3) diagnostic
confirmation of GIST through fine-needle aspiration
biopsy (FNAB) or if it is a KIT-positive tumor. When there
is a strong suspicion of gastric GIST based on endoscopic
ultrasonography without histological confirmation, sur-
gical resection or close follow-up may be considered [10].
Percutaneous biopsy is not encouraged, because it isGrade Grade of recommendation
A Evidence rated as level I or consistent findings
from multiple studies at levels II, III, or IV
ls with
ower)




C Evidence at levels II, III or IV, but inconsistent
findings
nd D Little or no systematic empirical evidence
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tumor dissemination [10].
Molecular pathologic diagnosis
Pathologically, the diagnosis of GIST can be confirmed
by morphology and immunohistochemistry. GISTs have
a characteristic immunohistochemical profile useful for
diagnosis [24]. Approximately 95% of GISTs are positive
for KIT, which makes KIT positivity a key defining fea-
ture of GIST, but alone it may not be sufficient to allow
diagnosis. Other commonly expressed markers include
CD34 antigen (70%), smooth muscle actin (SMA; 30
to 40%), desmin (<5%), and S100 protein (~5%) [24]. A
recently described antibody against Discovered on
GIST-1 (DOG1) has been reported to be as sensitive as
KIT in diagnosing GIST, but DOG1 is expressed only
in about 30% of KIT-negative GISTs, limiting its use in
this setting [25].
In the small proportion of GISTs (about 5%) that are
KIT-negative, or in patients with an unclear diagnosis or
atypical morphology or clinical features, mutational ana-
lysis for known mutations involving the KIT and PDGFRA
genes should be performed to confirm a diagnosis of GIST
[26]. Figure 1 shows an algorithm for the diagnosis
of GIST based on immunochemistry and mutational
analysis.
Imaging diagnosis and follow-up
Imaging is a useful diagnostic for confirming and sta-
ging GISTs and follow-up. Currently, all patients withwild-type 



















Figure 1 Recommended algorithm for the molecular diagnosis
of gastrointestinal stromal tumor by immunohistochemistry
and mutation analysis. Adapted from Miettinen et al. [25]. GIST,
gastrointestinal stromal tumor; PDGFRA, platelet-derived growth
factor receptor-α.suspected GIST should undergo abdominal/pelvic com-
puted tomography (CT) scanning with contrast and/or
magnetic resonance imaging (MRI). CT scanning is pre-
ferred over MRI if only one imaging procedure can be
performed. CT is also a sensitive and specific method
to assess the response of GISTs to imatinib treatment
[27]. When used for response evaluation, CT scan should
be based on a tailored standardized protocol, and the
assessment of therapeutic effect should include changes
in tumor size and density. 18F-fluorodeoxyglucose (FDG)-
positron emission tomography (PET) has also been shown
to be sensitive in detecting early response and to be use-
ful in assessing tumor response [9,28]. When CT scans
cannot be accurately evaluated, findings from FDG-PET
can be used to support the evaluation of the CT scan
reading. FDG-PET evaluation for treatment response
should be based on the uptake intensity of 18-FDG.
Risk stratification of primary GIST
Accurate risk classification of GISTs has become increas-
ingly important, owing to emerging adjuvant systemic
treatment. All GISTs are considered to have some malig-
nant potential, and there are several systems such as the
National Institute of Health (NIH) criteria, the Huang
modified NIH criteria, and the Armed Forces Institute
of Pathology (AFIP) criteria commonly used to deter-
mine the risk of recurrence. Joensuu et al. found in an
analysis of pooled population-based cohorts that all three
risk-stratification schemes were reasonably accurate at
predicting outcome. Those authors developed new prog-
nostic contour mapsbased on non-linear modeling of
tumor size and mitotic count, which might be useful for
estimation of individualized outcomes [29]. Of the three
risk-stratification systems, the AFIP criteria are consid-
ered the most informative for predicting the survival of
localized primary GISTs [22]. Thus the tumor size,
mitotic count per 50 high-power fields (HPFs) and tumor
location are considered the three most important prog-
nostic factors for prediction of GIST recurrence.
Recommendations for diagnosing GIST
Below are the general recommendations of the TSSG for
the diagnosis of GIST.
 In general, patients should be managed by a
multidisciplinary team (MDT) with expertise in
sarcoma. Shared decision-making between the MDT
and the patient is recommended.
 Initial investigations in patients with suspected GIST
should include history- taking and physical
examination, appropriate imaging of the abdomen
and pelvis using CT scan with contrast and/or MRI,
chest imaging, endoscopic ultrasonography, and
endoscopy, if not previously performed.
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those with tumors in the stomach, should be
referred for surgical resection.
 Patients with suspected gastric GIST 20 mm or
larger should receive surgical resection. It is strongly
suggested that those with suspected gastric nodules
of less than 20 mm in size are also referred tfor
resection if any of the following is present: 1) nodule
with signs of irregular margin, ulceration, bleeding
or increase in size during follow-up; 2) presence of
cystic change, necrosis, heterogeneous echogenecity,
lobulation, poor patient compliance with follow-up;
or 3) diagnostic confirmation of GIST by FNAB or
presence of KIT-positive tumor.
 When the diagnosis of gastric GIST is strongly
suspected based on endoscopic ultrasonography but
without histological confirmation, surgical resection
or close follow-up may be considered. Percutaneous
biopsy is not encouraged.
 Mutation analysis should be performed in
KIT-negative patients and in patients with an
unclear diagnosis or atypical clinical features.
 For imaging diagnosis and follow-up, CT scan is
preferred over MRI if only one imaging procedure
can be performed.
 When used for response evaluation, CT scan should
be based on a tailored standardized protocol, and
the assessment of therapeutic effect should include
changes in tumor size and density.
 FDG-PET can be used to support the CT scan
reading when the CT scan cannot be accurately
evaluated. FDG-PET evaluation for treatment
response should be based on the uptake intensity
of 18FDG.
Surgical treatment
Surgery remains the mainstay of therapy for patients
with primary GIST and no evidence of metastasis [9-11].
The goals of surgery include complete resection, avoid-
ance of tumor rupture, and intra-operative staging to
exclude metastatic disease.
The preferred resection margin is 10 mm grossly.
Lymph-node dissection is usually unnecessary because
lymph-node metastases are rare with GIST and indeed,
with sarcomas in general [30]. Preoperative biopsy is not
recommended for potentially resectable GIST, and is
associated with slight risks [9]. GISTs may be soft and
fragile, and biopsy may cause hemorrhage and increase
the risk of the tumor seeding. It is often difficult to
make a definitive diagnosis with FNAB, and a core needle
biopsy may be inconclusive if a necrotic or hemorrhagic
portion of the tumor is sampled. Therefore, postoperative
pathology assessment is crucial to confirm the diagnosis
after removal of any suspected GIST.Even after complete resection of primary localized GIST,
some patients are at high risk of tumor recurrence [1,8].
In a Taiwanese study of 85 patients with GIST who had
undergone complete resection, the 5-year disease-free sur-
vival (DFS) and overall survival (OS) rates were 43.7% and
50.5%, respectively [31]. Similar survival rates in the range
of 40 to 65% have been reported in other studies [1,32-36].
The role of surgery in patients with metastatic GIST
after treatment with imatinib has been evaluated in several
studies. Medical treatment of metastatic GIST with ima-
tinib alone usually does not result in complete response.
Furthermore, responses are not maintained indefinitely,
and resistance usually develops. Surgery after imatinib
treatment has been shown to prolong progression-free
survival (PFS) and OS in Taiwanese patients with res-
ponsive tumors or local progression [37]. Furthermore,
surgery for selected responsive lesions may play a role in
preventing potential development of secondary mutations,
which is the main reason for resistance and eventually
progression [37]. Similarly, Raut et al. found that surgery
prolonged OS in patients with advanced GIST exhibiting
stable disease or limited progression on imatinib therapy
[38]. Surgery did not result in any survival benefit in
patients with generalized disease progression [38].
Therefore, the combined use of surgery and imatinib
treatment may be beneficial for selected patients with
metastatic GIST if the disease is responsive to imatinib,
or if progression is localized. Surgery is not indicated in
systemic progressive disease, unless for complications
such as obstruction, bleeding, or perforation [9].
Recommendations for surgical treatment
Hence, the recommendations for surgical treatment are
as follows.
 The surgical goals for resectable GIST include
complete resection, avoidance of tumor rupture, and
intra-operative staging to exclude metastatic disease.
The preferred resection margin is 10 mm grossly.
Lymph-node dissection is unnecessary.
 Combined use of surgery with imatinib treatment
may benefit selected patients with metastatic GIST
that is responsive to imatinib and exhibits only
localized progression [level of evidence IIIB].
 Surgery with imatinib treatment is not indicated for
systemic progressive disease unless for complications
such as obstruction, bleeding, or perforation.
 Biopsy is not recommended for potentially
resectable GIST.
Medical treatment
Adjuvant treatment Postoperative adjuvant chemother-
apy with conventional cytotoxic agents has not generally
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ineffective against the cancer [8]. In view of the like-
lihood of tumor recurrence after surgical resection,
several studies have investigated the role of adjuvant
imatinib treatment in GIST, and suggested that it is
useful in patients at significant risk of recurrence after
tumor resection [39-41]. Imatinib is an oral agent that
is a selective molecular inhibitor of the KIT, PDGFRA,
ABL, and BCR-ABL tyrosine kinases. Imatinib was first
used for chronic myelogenous leukemia, for which it
proved to be safe and to be capable of achieving complete
hematological response in nearly all patients through in-
hibition of the BCR-ABL oncoprotein [42]. The efficacy
of imatinib against metastatic GIST was first shown in
2000 [32], and subsequently confirmed in phase II and
phase III trials in metastatic disease [43-46].
The American College of Surgeons Oncology Group
(ACOSOG) first conducted an open-label, multicenter,
phase II trial (Z9000) to evaluate the efficacy of post-
operative imatinib in 106 evaluable patients with pri-
mary GIST who were at high risk for recurrence (tumor
size ≥100 mm, tumor rupture, or <5 peritoneal meta-
stases) [39]. The results showed that postoperative
imatinib 400 mg daily for 1 year prolonged recurrence-
free survival (RFS) after complete resection, and was also
associated with improved OS compared with historical
controls. A subsequent ACOSOG phase III, double-
blind, randomized trial (Z9001) in patients with KIT-
expressing GIST of at least 30 mm in size confirmed that
1 year of adjuvant imatinib (400 mg/day) significantly
improved 1-year RFS rates after complete resection com-
pared with placebo (98% versus 83%, P<0.0001) [40].
Based on the Z9001 phase III data, imatinib (400 mg/day)
has been approved by the US Food and Drugs Adminis-
tration (FDA) for the adjuvant treatment of adult patients
after complete surgical removal of KIT-positive GISTs
[47]. A recent randomized, open-label, phase III study
(SSGXVIII/AIO) evaluated adjuvant imatinib therapy
for 3 years compared with 1 year in patients with KIT-
positive GIST removed by surgery who were at high risk
of recurrence (tumor size >100 mm or tumor with a
mitotic rate of >10 mitoses/50 HPFs or tumor size
>50 mm and a mitotic rate of >5 mitoses/50 HPFs or
tumor rupture) [41]. The results showed that 3 years of
adjuvant imatinib significantly improved the 5-year RFS
(65.6% vs 27.9%, p<0.001) and OS (92.0% versus 81.7%,
P<0.02) compared with 1-year imatinib therapy. The role
of longer-term treatment and the optimal duration of
adjuvant imatinib remain to be determined by further
studies. Based on current clinical evidence, adjuvant
imatinib is recommended for intermediate (≥60 ,m and
<100 mm) to high-risk primary GISTs (mitotic count
>5 mitoses/50 HPFs; size >50 mm; non-gastric location;
and tumor rupture), and treatment duration and criteriausually follow the guidelines for national health insur-
ance reimbursement in Taiwan.
Recurrent or metastatic disease In agreement with the
NCCN and ESMO guidelines, we recommend that ima-
tinib should be used as first-line therapy for unresect-
able, recurrent, or metastatic GIST [9-11]. Recurrence is
common after surgical resection of primary GIST, and
the site of first recurrence is typically within the abdo-
men and involves the peritoneum, liver or both. Before
the era of imatinib, treatment options for patients with
recurrent or metastatic disease were limited because of
the poor response of GISTs to conventional chemother-
apy and radiotherapy, making their outlook very poor.
The median time to recurrence after resection was
approximately 2 years [1,36].
The clinical benefit of imatinib has been shown in
western and East Asian patients with advanced unresect-
able or metastatic GIST. The phase II randomized trial
(B2222) and subsequent long-term follow-up analysis
showed that imatinib 400 mg or 600 mg daily induced a
sustained objective response in more than half of patients
with advanced unresectable or metastatic GIST, extend-
ing the median survival to 57 months [43,44]. Similar
benefits were achieved in patients who had objective
responses and patients who had stable disease [44]. The
optimal dose of imatinib was further investigated in
two multicenter, randomized phase III trials, (S0033
and the European Organisation for Research and Treat-
ment of Cancer (EORTC) study 62005), which compared
standard-dose (400 mg daily) with high-dose (800 mg
daily) imatinib, with the option for patients whose dis-
ease progressed on the standard dose to cross over to the
high dose [44,45]. Results from the trials confirmed the
effectiveness of imatinib as primary therapy for advanced
or metastatic GIST, but both the S0033 trial and the
longer-term follow-up analysis of the EORTC 62005
did not show a significant advantage for the high-dose
treatment [42,46]. A subsequent meta-analysis of 1,640
patients with advanced GIST from the S0033 and
EORTC 62005 trials (MetaGIST) showed a small PFS
advantage of high-dose imatinib, essentially for patients
with KIT exon 9 mutations, but no OS advantage [47].
Studies in Taiwanese patients confirmed the survival
benefits of imatinib in patients with advanced GIST. An
early study in 22 patients with advanced GIST showed
that patients treated with imatinib 400 mg daily had a
significantly longer post-recurrence survival and OS
compared with those not treated with imatinib [48].
The partial response rate was 68.2%, and this was similar
for patients with KIT exon 9 and those with KIT exon
11 mutations. A longer-term study of 171 Taiwanese
patients with advanced or metastatic GIST treated and
followed up within a 10-year period (median follow-up
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objective response in more than half of the patients
(57.4%) [49,50]. The median PFS and OS rates were 37.6
and 71.0 months, respectively. Similar to the MetaGIST
study, the clinical benefit of imatinib was significantly
higher in patients harboring KIT exon 11 mutations than
in those harboring KIT exon 9 mutations (93.3% versus
61.9%, P = 0.0005), suggesting that patients with KIT
exon 9 mutations may benefit from escalating the imati-
nib dose to 800 mg daily [47].
Neoadjuvant treatment Neoadjuvant imatinib treatment
may reduce tumor size or spread, and enable patients
with previously unresectable GISTs to undergo surgical
resection. Two phase II trials have evaluated the efficacy
and safety of preoperative imatinib for GIST. The Radi-
ation Therapy Oncology Group (RTOG) prospective
phase II study (RTOG 0132) was the first to evaluate the
neoadjuvant use of imatinib 600 mg/day for patients with
advanced primary GIST (n = 30) and the preoperative
use of imatinib in patients with potentially operable
metastatic/recurrent disease (n = 22) [51]. Response rates
after 8 weeks of preoperative imatinib in accordance
with the Response Evaluation Criteria in Solid Tumors
(RECIST) system were 7% partial and 83% stable dis-
ease., while the corresponding response rates in patients
with recurrent or metastatic disease were 4.5% and 91%,
respectively. The 2-year PFS rates were 83% for patients
with primary GIST and 77% for those with recurrent or
metastatic GIST, and the estimated OS rates were 93%
and 91%, respectively. Complications of surgery and ima-
tinib toxicity were reported to be minimal.
Another phase II trial randomized 19 patients with
GIST undergoing surgical resection to receive 3, 5, or
7 days of preoperative imatinib 600 mg daily. All patients
received postoperative imatinib for 2 years [52]. The
response rates as assessed by 18FPG-PET and dynamic
CT were 69% and 71%, respectively. Median DFS of
patients treated with surgery and imatinib was 46 months,
and imatinib did not affect surgical morbidity com-
pared with an imatinib-naive cohort. The true survival
benefit of preoperative imatinib could not be determined
because all patients received postoperative imatinib for
2 years in both trials. The optimal duration of pre-
operative imatinib also needs to be defined.
Neoadjuvant imatinib should be considered for patients
with marginally resectable tumors or resectable GISTs
who have a risk of significant morbidity [9]. Neoadjuvant
imatinib can also be considered for patient with primary
localized GIST whose tumors are deemed unresectable.
The decision to use preoperative therapy for patients
with resectable primary or locally advanced GIST should
be made based on clinical judgment and on an individ-
ual basis. When neoadjuvant treatment is considered,progression and response of tumors before and during
the treatment should be assessed carefully by an MDT,
based on CT (with optional MRI) scan and/or PET scan
results. Early assessment of tumor response is recom-
mended, so that surgery is not delayed in the case of
non-responding tumors. Continuous imatinib treatment
should be considered for patients with GISTif adminis-
tered before resection and if an objective response is
obtained.
Second-line treatment of advanced GISTs Regarding
disease progression during imatinib therapy, resection of
the progressing lesion should be considered if it is feas-
ible and progression is limited [38]. For patients with
limited progressive disease, or those with generalized
progressive disease and good performance status (0 to 2),
options include continuation of imatinib at the same
dose, dose escalation as tolerated (600 to 800 mg/day),
or switching to sunitinib after failure on imatinib [9-11].
Radiofrequency ablation and chemoembolization can
also be considered for patients with limited progressive
disease [9,10]. Treatment response should be reassessed
carefully by CT or PET scan.
Sunitinib is an oral multi-targeted tyrosine kinase
inhibitor with activity against KIT and PDGFRA as well
as other pathways that may be relevant in GIST, such as
vascular endothelial growth factor receptor [53,54].
Sunitinib has received multinational approval for the
treatment of GIST after failure of imatinib due to resist-
ance or intolerance, based on the results of an inter-
national, randomized, double-blind, placebo-controlled
phase III trial [55]. The trial results showed that sunitinib
50 mg daily in a 4/2 schedule (4 weeks on and 2 weeks
off treatment) significantly prolonged the time to pro-
gression compared with placebo in patients with ad-
vanced GIST who were resistant or intolerant to imatinib
(27.3 weeks versus 6.4 weeks, P<0.0001). Continuous
daily dosing with sunitinib 37.5 mg daily has also been
reported to be active, and compares favorably with the
4/2 schedule [56]. A retrospective study in Taiwanese
patients with imatinib-resistant or imatinib-intolerant
GIST showed that sunitinib induced a sustained clini-
cal benefit in 65.2% of the patients, and the median PFS
and OS were 8.4 and 14.1 months, respectively [57].
There are also some newer agents that are under in-
vestigation for the treatment of GISTs. These include
the second-generation tyrosine kinase inhibitors niloti-
nib, dasatinib, and sorafenib [9,10].
Recommendations for medical treatment
 Adjuvant imatinib treatment should be considered
in high-risk patients after complete or incomplete
resection of primary tumor [level of evidence IIB].
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patients with: 1) marginally resectable tumors or
resectable GISTs, who have a risk of significant
morbidity; or 2) primary localized GIST, whose
tumors are deemed unresectable.
 When neoadjuvant treatment is considered,
progression and response of tumors before and
during the treatment should be assessed by the
MDT, using CT (with optional MRI) and/or PET
scans.
 Imatinib 400 mg daily should be initiated as first-line
therapy for recurrent or metastatic GIST [level of
evidence IA]. Higher doses, up to 800 mg daily,
should be considered for patients with exon 9 KIT
mutation [IIIA].
 In case of limited disease progression during
imatinib therapy, resection of progressing lesion
should be considered if feasible. Radiofrequency
ablation and chemoembolization can be considered
to control limited progression. Imatinib should be
continued at the same dose or at an increased dose
(600 to 800 mg/day) [level of evidence IIIB], as
tolerated. After failure on imatinib, sunitinib can be
considered as second-line therapy [IIB].Figure 2 The treatment procedure for gastrointestinal stromal tumor
Gastroenterology. In patients with generalized progressive disease and
performance status 0 to 2, imatinib should be
administered at a higher dose (600 to 800 mg/day),
as tolerated [level of evidence IIIB], and sunitinib
should be considered after failure of imatinib [IIB].
Treatment response after progression should be
reassessed carefully by CT or PET scan.
Conclusion
The TSSG recommends that patients with GIST should
be managed by an MDT with expertise in sarcoma, and
the recommended treatment flow is shown in Figure 2.
Importantly, mutation analysis should be considered in
selected patients with primary disease to confirm the
diagnosis of KIT-positive GISTs with atypical morphology
or clinical features, or of KIT-negative GISTs, and to
identify patients at higher risk of recurrence if consid-
ering postoperative imatinib therapy after resection of
the primary tumor. For the treatment of GIST, surgery
remains the mainstay therapy for resectable tumors.
Imatinib treatment can substantially prolong survival
of patients with unresectable or metastatic GIST, and
is associated with mostly mild and manageable adverse
effects. Thus, imatinib should be considered as first-line(GIST) recommended by the Taiwan Surgical Society of
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vant imatinib treatment may also be considered for
patients with GIST.
Several clinical practice guidelines for GIST are now
available, based on country-specific clinical practice, in-
cluding those by the NCCN, ESMO, Korean GIST Study
Group [58], and Japan Society of Clinical Oncology59. The
guidelines presented here represent the updated recom-
mendations of the TSSG for Taiwanese patients. Prepared
through a series of meetings involving multidisciplinary
experts across Taiwan, the recommendations have taken
into account recent evidence in the diagnosis and surgical
and medical treatment for GIST, and are tailored to clin-
ical practice in Taiwan. The guidelines are intended to
provide guidance for physicians in decision-making and
providing optimal care and treatment for patients with
GIST patients in Taiwan.
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